CA3198173A1 - Combinations of metap2 inhibitors and cdk4/6 inhibitors for the treatment of cancer - Google Patents
Combinations of metap2 inhibitors and cdk4/6 inhibitors for the treatment of cancerInfo
- Publication number
- CA3198173A1 CA3198173A1 CA3198173A CA3198173A CA3198173A1 CA 3198173 A1 CA3198173 A1 CA 3198173A1 CA 3198173 A CA3198173 A CA 3198173A CA 3198173 A CA3198173 A CA 3198173A CA 3198173 A1 CA3198173 A1 CA 3198173A1
- Authority
- CA
- Canada
- Prior art keywords
- inhibitor
- cancer
- cdk4
- pharmaceutically acceptable
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063112217P | 2020-11-11 | 2020-11-11 | |
| US63/112,217 | 2020-11-11 | ||
| US202163166060P | 2021-03-25 | 2021-03-25 | |
| US63/166,060 | 2021-03-25 | ||
| PCT/US2021/058775 WO2022103834A1 (en) | 2020-11-11 | 2021-11-10 | Combinations of metap2 inhibitors and cdk4/6 inhibitors for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3198173A1 true CA3198173A1 (en) | 2022-05-19 |
Family
ID=78821168
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3198173A Pending CA3198173A1 (en) | 2020-11-11 | 2021-11-10 | Combinations of metap2 inhibitors and cdk4/6 inhibitors for the treatment of cancer |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230404963A1 (https=) |
| EP (1) | EP4243807A1 (https=) |
| JP (1) | JP2023550035A (https=) |
| KR (1) | KR20230117574A (https=) |
| AU (1) | AU2021378944A1 (https=) |
| CA (1) | CA3198173A1 (https=) |
| MX (1) | MX2023005501A (https=) |
| WO (1) | WO2022103834A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250127759A1 (en) * | 2021-12-02 | 2025-04-24 | Pfizer Inc. | Methods and dosing regimens comprising a cdk2 inhibitor for the treatment of cancer |
| CA3264343A1 (en) * | 2022-08-10 | 2024-02-15 | Syndevrx, Inc. | METAP2 INHIBITORS FOR THE TREATMENT OF PULMONARY FIBROSIS |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5763263A (en) | 1995-11-27 | 1998-06-09 | Dehlinger; Peter J. | Method and apparatus for producing position addressable combinatorial libraries |
| US20130137831A1 (en) * | 2010-05-25 | 2013-05-30 | John S. Petersen | Optimized drug conjugates |
| CA3239447A1 (en) * | 2016-01-11 | 2017-07-20 | Syndevrx, Inc. | Treatment for tumors driven by metabolic dysfunction |
| WO2019070755A1 (en) * | 2017-10-02 | 2019-04-11 | The Broad Institute, Inc. | METHODS AND COMPOSITIONS FOR DETECTING AND MODULATING A GENETIC SIGNATURE OF IMMUNOTHERAPY RESISTANCE IN CANCER |
| JP2022512826A (ja) * | 2018-10-26 | 2022-02-07 | シンデブルックス，インコーポレイティド | ＭｅｔＡＰ２阻害剤のバイオマーカーとその応用 |
-
2021
- 2021-11-10 WO PCT/US2021/058775 patent/WO2022103834A1/en not_active Ceased
- 2021-11-10 AU AU2021378944A patent/AU2021378944A1/en active Pending
- 2021-11-10 US US18/036,565 patent/US20230404963A1/en active Pending
- 2021-11-10 JP JP2023528148A patent/JP2023550035A/ja active Pending
- 2021-11-10 KR KR1020237018920A patent/KR20230117574A/ko active Pending
- 2021-11-10 EP EP21819673.1A patent/EP4243807A1/en active Pending
- 2021-11-10 MX MX2023005501A patent/MX2023005501A/es unknown
- 2021-11-10 CA CA3198173A patent/CA3198173A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021378944A1 (en) | 2023-06-15 |
| US20230404963A1 (en) | 2023-12-21 |
| MX2023005501A (es) | 2023-07-27 |
| EP4243807A1 (en) | 2023-09-20 |
| JP2023550035A (ja) | 2023-11-30 |
| WO2022103834A1 (en) | 2022-05-19 |
| KR20230117574A (ko) | 2023-08-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240180919A1 (en) | Ezh2 inhibitors for treating cancer | |
| US20250152598A1 (en) | Method for treating cancer | |
| US20220175789A1 (en) | Ezh2 inhibitors for treating lymphoma | |
| US20200330472A1 (en) | Method of treating cancer | |
| JP2020011971A (ja) | ガンの治療方法 | |
| AU2022202118A1 (en) | Method for treating cancer | |
| TW202342454A (zh) | 一種多功能化合物、其製備方法及其在醫藥上的應用 | |
| BR112020011914A2 (pt) | inibidores de via de resposta de tensão integrada | |
| AU2015217152A1 (en) | Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease | |
| CN111303133A (zh) | 降解ezh2蛋白的小分子化合物 | |
| CA3198173A1 (en) | Combinations of metap2 inhibitors and cdk4/6 inhibitors for the treatment of cancer | |
| WO2015197006A1 (zh) | 一种取代的氨基酸硫酯类化合物、其组合物及应用 | |
| WO2020077361A1 (en) | Compounds and methods of their use | |
| CN111253412A (zh) | α-倒捻子素衍生物及其应用 | |
| EP4076466B1 (en) | Modulators of cullin 3 adaptor kbtbd4 as anti-cancer compounds | |
| CN105764522A (zh) | Nmda受体调节剂及其前药、盐和用途 | |
| CN116887836A (zh) | 用于治疗癌症的metap2抑制剂和cdk4/6抑制剂的组合 | |
| WO2026080654A1 (en) | Technologies targeting cell states | |
| TW201706279A (zh) | 經取代的氨基磷酸酯類衍生物、其製備方法及其應用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241101 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241101 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241101 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251031 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251031 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20251110 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20251110 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251110 |